Correlation Between Swedish Orphan and CellaVision

Can any of the company-specific risk be diversified away by investing in both Swedish Orphan and CellaVision at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Swedish Orphan and CellaVision into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Swedish Orphan Biovitrum and CellaVision AB, you can compare the effects of market volatilities on Swedish Orphan and CellaVision and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Swedish Orphan with a short position of CellaVision. Check out your portfolio center. Please also check ongoing floating volatility patterns of Swedish Orphan and CellaVision.

Diversification Opportunities for Swedish Orphan and CellaVision

0.05

Correlation Coefficient

Swedish Orphan  CellaVision

Significant diversification

The 3 months correlation between Swedish and CellaVision is 0.05. Overlapping area represents the amount of risk that can be diversified away by holding Swedish Orphan Biovitrum and CellaVision AB in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on CellaVision AB and Swedish Orphan is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Swedish Orphan Biovitrum are associated (or correlated) with CellaVision. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of CellaVision AB has no effect on the direction of Swedish Orphan i.e., Swedish Orphan and CellaVision go up and down completely randomly.

Pair Corralation between Swedish Orphan and CellaVision

Assuming the 90 days trading horizon Swedish Orphan Biovitrum is expected to generate 0.92 times more return on investment than CellaVision. However, Swedish Orphan Biovitrum is 1.09 times less risky than CellaVision. It trades about 0.0 of its potential returns per unit of risk. CellaVision AB is currently generating about -0.13 per unit of risk. If you would invest  30,960  in Swedish Orphan Biovitrum on September 4, 2024 and sell it today you would lose (420.00) from holding Swedish Orphan Biovitrum or give up 1.36% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Swedish Orphan Biovitrum  vs.  CellaVision AB

Swedish Orphan Biovitrum

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Swedish Orphan Biovitrum has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Swedish Orphan is not utilizing all of its potentials. The current stock price uproar, may contribute to short-horizon losses for the private investors.

CellaVision AB

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days CellaVision AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in January 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Pair Trading with Swedish Orphan and CellaVision

The main advantage of trading using opposite Swedish Orphan and CellaVision positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Swedish Orphan position performs unexpectedly, CellaVision can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CellaVision will offset losses from the drop in CellaVision's long position.

The idea behind Swedish Orphan Biovitrum and CellaVision AB pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.